Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 8, 2026
Turn Therapeutics Inc. (TTRX)
A forensic read on Turn Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Distress
Financial health
-9.0
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-117.3%
ROE
$282M
Market cap
Turn Therapeutics Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is -9.0, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-217%Return on invested capital.Return on invested capital is -217% in the latest fiscal year and slipping from -168% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+4.0%/yrShare-count dilution.Diluted share count changed +4% over the last 1 years to FY2025 (+4.0%/yr). The count is GROWING — existing holders are being diluted. That's ~4.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~4%.
Key fundamentals
Return on Equity-68.2%
Debt / Equity1.27x
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Turn Therapeutics Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about TTRX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown